Skip to main content

Table 3 Baseline features of EGPA patients with and without CNS involvement

From: Clinical features of central nervous system involvement in patients with eosinophilic granulomatosis with polyangiitis: a retrospective cohort study in China

Characteristics With CNS involvement (n = 19) Without CNS involvement (n = 91) P value
Demographics    
Age (year) 51.7 ± 11.56 43.7 ± 13.78 0.019*
Gender (male/female, number) 10/9 51/40 0.490
Time from allergy to EGPA
diagnosis (month)
48 (5, 115) 24 (5, 60) 0.314
Disease duration (month) 11 (4, 39) 5 (2, 14) 0.082
Time from initial symptoms to vasculitis (month) 21 (2, 54) 7 (0, 36) 0.337
Clinical manifestation, n (%)    
Weight loss 6 (31.6) 35 (38.5) 0.573
Fever 11 (57.9) 34 (37.4) 0.098
Arthritis 4 (21.1) 13 (14.3) 0.489
Myalgia 6 (31.6) 16 (17.6) 0.207
Allergic rhinitis 6 (31.6) 34 (37.4) 0.634
Severe asthma 13 (68.4) 72 (79.1) 0.368
Cutaneous vasculitis 11 (57.9) 48 (52.7) 0.682
Renal involvement 4 (21.1) 24 (26.4) 0.776
Digestive tract involvement 10 (52.6) 26 (28.6) 0.042*
Peripheral neuropathy 11 (57.9) 40 (44.0) 0.268
Cardiac involvement 5 (26.3) 35 (38.5) 0.317
Ear involvement 4 (21.1) 10 (11.0) 0.258
Sinusitis 11 (57.9) 53 (58.2) 0.978
Laboratory examination    
Eos count (109/L) 4.1 (1.5,5.6) 2.6 (1.4,7.6) 0.770
Eos% 37.2 (11.8,50.0) 28.6 (17.1,45.7) 0.483
ESR (mm/1 h) 27 (9,40) 32 (14,54) 0.461
CRP (mg/L) 10.84 (5.34,39.77) 21.70 (4.54,63.85) 0.623
RF (IU/mL) 21.7 (7.0,90.1) 25.0 (10.0,90.4) 0.651
MPO-ANCA, n (%) 3 (15.8) 12 (13.2) 0.721
PR3-ANCA, n (%) 1 (5.3) 1 (1.1) 0.317
Biopsy-proven vasculitis 4 (21.1) 10 (11.0) 0.258
Granuloma, n (%) 1 (5.3) 5 (5.5) 1.000
Clinical score    
BVAS 16 (14,22) 14 (10,19) 0.103
FFS ≥ 1, n (%) 16 (84.2) 65 (71.4) 0.250
  1. All the continuous normally distributed data are presented as mean ± standard deviation, and non-normally distributed data as median (first quartile, third quartile)
  2. EGPA, Eosinophilic Granulomatosis with Polyangiitis; CNS, Central Nervous System; Eos, eosinophil; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; MPO, myeloperoxidase; ANCA, anti-neutrophil cytoplasmic antibody; PR3, protease 3; BVAS, Birmingham Vasculitis Activity Score; FFS, five -factor score; *P < 0.05.
\